KRAS and lung adenocarcinoma: Migration and invasion are similarly reduced in invasive cells of wildtype KRAS (H1650 and H1975) after AMG900 treatment (two-way ANOVA test p < 0.0001 for dose of 0.1 and 1 μM, SFig. 9b) suggesting that pan-aurora kinase inhibition suppresses invasiveness in lung adenocarcinoma cells independent of KRAS driver mutation status.